Patient-derived Organoids for Oncology Drug Development: What You Need to Know
Many oncology drug candidates fail in the clinic, partly because screening models don’t capture the biology and heterogeneity of real tumors. Patient-derived organoids offer a middle ground: they’re more disease-relevant than cell lines, and faster and more scalable than xenografts. Find out how to get the most out of them in your drug screen.

